APLS
Apellis Pharmaceuticals Inc

3,696
Mkt Cap
$2.46B
Volume
2.28M
52W High
$35.72
52W Low
$16.10
PE Ratio
65.51
APLS Fundamentals
Price
$19.54
Prev Close
$19.45
Open
$19.68
50D MA
$23.48
Beta
1.02
Avg. Volume
2.89M
EPS (Annual)
-$1.60
P/B
6.13
Rev/Employee
$1.1M
Loading...
Loading...
News
all
press releases
Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells $100,300.00 in Stock
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) General Counsel David Watson sold 5,000 shares of Apellis Pharmaceuticals stock in a transaction on Monday, November 17th. The stock was...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Hold" from Brokerages
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eighteen research firms that are presently covering the firm, MarketBeat...
MarketBeat·10d ago
News Placeholder
Wall Street Zen Upgrades Apellis Pharmaceuticals (NASDAQ:APLS) to "Buy"
Wall Street Zen upgraded shares of Apellis Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday...
MarketBeat·13d ago
News Placeholder
Apellis Pharmaceuticals (NASDAQ:APLS) Now Covered by Analysts at Wolfe Research
Wolfe Research initiated coverage on shares of Apellis Pharmaceuticals in a research note on Thursday. They issued a "peer perform" rating for the company...
MarketBeat·13d ago
News Placeholder
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $36.00 by Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. decreased their price target on shares of Apellis Pharmaceuticals from $40.00 to $36.00 and set an "overweight" rating for the company in a research note on Wednesday...
MarketBeat·14d ago
News Placeholder
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment.
Zacks·20d ago
News Placeholder
Apellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Apellis Pharmaceuticals (APLS) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·21d ago
News Placeholder
Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of +62.14% and +25.22%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·21d ago
News Placeholder
Exact Sciences (EXAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·24d ago
News Placeholder
Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth
Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·28d ago

Latest APLS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.